妊娠早期中性粒细胞百分比-白蛋白比率：一种新的子痫前期预测指标。

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-06-01 Epub Date: 2025-05-25 DOI:10.1080/17520363.2025.2511468

Çağlayan Biçer, Fatih Akkuş, Yusuf Dal

{"title":"妊娠早期中性粒细胞百分比-白蛋白比率：一种新的子痫前期预测指标。","authors":"Çağlayan Biçer, Fatih Akkuş, Yusuf Dal","doi":"10.1080/17520363.2025.2511468","DOIUrl":null,"url":null,"abstract":"Objective: This retrospective study evaluated the predictive power of a new marker for pre-eclampsia (PE), the neutrophil percentage/albumin ratio (NPAR).Methods: A total of 399 participants consisting of 133 pregnant women diagnosed with PE and 266 healthy pregnant controls were included in the study. Data collected included demographic and obstetric history, gestational age at diagnosis, maternal hematological and biochemical parameters, first trimester neutrophil/albumin ratio (NAR) and NPAR values, and neonatal outcomes.Results: The pre-eclampsia group showed significantly higher NAR (mean: 312.30, range: 80.00-1568.00) and NPAR (mean: 3.14 ± 0.81) compared to the control group (mean NAR: 234.40, range: 78.16-725.00; mean NPAR: 2.06 ± 0.38; p = 0.001 for both). Furthermore, early-onset PE was associated with significantly higher NAR (395.00 vs. 256.23, p = 0.001) and NPAR (3.87 vs. 2.80, p = 0.001) compared to late-onset PE. For early-onset PE, NPAR showed a sensitivity of 76.19%, specificity of 92.31%, PPV of 82.05%, NPV of 89.36% and area under the curve (AUC) of 0.897, demonstrating its strong potential as an early predictor of pre-eclampsia.Conclusion: NPAR is elevated in PE compared to healthy pregnancies, demonstrating its potential as a simple yet effective biomarker for predicting PE.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"415-423"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140476/pdf/","citationCount":"0","resultStr":"{\"title\":\"First-trimester neutrophil percentage-to-albumin ratio: a novel predictor for preeclampsia.\",\"authors\":\"Çağlayan Biçer, Fatih Akkuş, Yusuf Dal\",\"doi\":\"10.1080/17520363.2025.2511468\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: This retrospective study evaluated the predictive power of a new marker for pre-eclampsia (PE), the neutrophil percentage/albumin ratio (NPAR).Methods: A total of 399 participants consisting of 133 pregnant women diagnosed with PE and 266 healthy pregnant controls were included in the study. Data collected included demographic and obstetric history, gestational age at diagnosis, maternal hematological and biochemical parameters, first trimester neutrophil/albumin ratio (NAR) and NPAR values, and neonatal outcomes.Results: The pre-eclampsia group showed significantly higher NAR (mean: 312.30, range: 80.00-1568.00) and NPAR (mean: 3.14 ± 0.81) compared to the control group (mean NAR: 234.40, range: 78.16-725.00; mean NPAR: 2.06 ± 0.38; p = 0.001 for both). Furthermore, early-onset PE was associated with significantly higher NAR (395.00 vs. 256.23, p = 0.001) and NPAR (3.87 vs. 2.80, p = 0.001) compared to late-onset PE. For early-onset PE, NPAR showed a sensitivity of 76.19%, specificity of 92.31%, PPV of 82.05%, NPV of 89.36% and area under the curve (AUC) of 0.897, demonstrating its strong potential as an early predictor of pre-eclampsia.Conclusion: NPAR is elevated in PE compared to healthy pregnancies, demonstrating its potential as a simple yet effective biomarker for predicting PE.\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"415-423\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140476/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2511468\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2511468","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：本回顾性研究评估中性粒细胞百分比/白蛋白比率（NPAR）作为子痫前期（PE）新标志物的预测能力。方法：共纳入399名参与者，包括133名诊断为PE的孕妇和266名健康孕妇对照。收集的数据包括人口统计学和产科史、诊断时的胎龄、产妇血液学和生化参数、妊娠早期中性粒细胞/白蛋白比（NAR）和NPAR值以及新生儿结局。结果：子痫前期组NAR（平均值：312.30，范围：80.00 ~ 1568.00）和NPAR（平均值：3.14±0.81）明显高于对照组(平均值：234.40，范围：78.16 ~ 725.00；平均NPAR: 2.06±0.38；P = 0.001)。此外，与晚发性PE相比，早发性PE的NAR（395.00比256.23,p = 0.001）和NPAR（3.87比2.80,p = 0.001）显著升高。对于早发性PE， NPAR的敏感性为76.19%，特异性为92.31%，PPV为82.05%，NPV为89.36%，曲线下面积（AUC）为0.897，显示了其作为先兆子痫早期预测指标的强大潜力。结论：与健康妊娠相比，NPAR在PE中升高，表明其作为预测PE的简单而有效的生物标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

First-trimester neutrophil percentage-to-albumin ratio: a novel predictor for preeclampsia.

Objective: This retrospective study evaluated the predictive power of a new marker for pre-eclampsia (PE), the neutrophil percentage/albumin ratio (NPAR).

Methods: A total of 399 participants consisting of 133 pregnant women diagnosed with PE and 266 healthy pregnant controls were included in the study. Data collected included demographic and obstetric history, gestational age at diagnosis, maternal hematological and biochemical parameters, first trimester neutrophil/albumin ratio (NAR) and NPAR values, and neonatal outcomes.

Results: The pre-eclampsia group showed significantly higher NAR (mean: 312.30, range: 80.00-1568.00) and NPAR (mean: 3.14 ± 0.81) compared to the control group (mean NAR: 234.40, range: 78.16-725.00; mean NPAR: 2.06 ± 0.38; p = 0.001 for both). Furthermore, early-onset PE was associated with significantly higher NAR (395.00 vs. 256.23, p = 0.001) and NPAR (3.87 vs. 2.80, p = 0.001) compared to late-onset PE. For early-onset PE, NPAR showed a sensitivity of 76.19%, specificity of 92.31%, PPV of 82.05%, NPV of 89.36% and area under the curve (AUC) of 0.897, demonstrating its strong potential as an early predictor of pre-eclampsia.

Conclusion: NPAR is elevated in PE compared to healthy pregnancies, demonstrating its potential as a simple yet effective biomarker for predicting PE.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.